BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29097943)

  • 21. Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
    Alexander N; Marrano P; Thorner P; Naranjo A; Van Ryn C; Martinez D; Batra V; Zhang L; Irwin MS; Baruchel S
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):222-227. PubMed ID: 30334904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary PET/CT Imaging with Somatostatin Analogs [
    Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
    Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.
    Murphy R; Chander G; Martinez M; Ward C; Khan SR; Naik M; Barwick T; Aboagye E; Sharma R
    BMJ Open; 2023 Oct; 13(10):e075221. PubMed ID: 37879695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
    Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
    Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
    Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
    Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
    Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
    Bandara N; Jacobson O; Mpoy C; Chen X; Rogers BE
    Bioconjug Chem; 2018 Jul; 29(7):2448-2454. PubMed ID: 29927587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
    Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
    J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
    Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
    Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
    Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
    J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE.
    Koumarianou E; Pawlak D; Korsak A; Mikolajczak R
    Nucl Med Rev Cent East Eur; 2011; 14(2):85-9. PubMed ID: 22219148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3p-C-NETA: A versatile and effective chelator for development of Al
    Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
    Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
    [No Abstract]   [Full Text] [Related]  

  • 39. The Search for an Alternative to [
    Waldmann CM; Stuparu AD; van Dam RM; Slavik R
    Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
    Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
    PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.